Luo YH - Search Results

1

Oncogenic circRNA C190 Promotes Non-Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway.

Ishola AA, Chien CS, Yang YP, Chien Y, Yarmishyn AA, Tsai PH, Chen JC, Hsu PK, Luo YH, Chen YM, Liang KH, Lan YT, Huo TI, Ma HI, Chen MT, Wang ML, Chiou SH. Ishola AA, et al. Among authors: luo yh. Cancer Res. 2022 Jan 1;82(1):75-89. doi: 10.1158/0008-5472.CAN-21-1473. Epub 2021 Nov 9. Cancer Res. 2022. PMID: 34753774

2

Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs.

Luo YH, Wu CH, Wu WS, Huang CY, Su WJ, Tsai CM, Lee YC, Perng RP, Chen YM. Luo YH, et al. J Thorac Oncol. 2012 Feb;7(2):299-305. doi: 10.1097/JTO.0b013e31823c588d. J Thorac Oncol. 2012. PMID: 22173705 Free article.

3

Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations.

Wu WS, Chen YM, Tsai CM, Shih JF, Chiu CH, Chou KT, Lai SL, Wu CH, Luo YH, Huang CY, Lee YC, Perng RP, Whang-Peng J. Wu WS, et al. Among authors: luo yh. Exp Ther Med. 2012 Feb;3(2):207-213. doi: 10.3892/etm.2011.383. Epub 2011 Nov 16. Exp Ther Med. 2012. PMID: 22969870 Free PMC article.

4

The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs.

Luo YH, Ho HL, Tsai CM, Shih JF, Chiu CH, Lai SL, Lee YC, Perng RP, Whang-Peng J, Chou TY, Chen YM. Luo YH, et al. Am J Clin Oncol. 2015 Apr;38(2):147-51. doi: 10.1097/COC.0b013e318292f88c. Am J Clin Oncol. 2015. PMID: 23608835

5

Influence of chemotherapy on EGFR mutation status.

Luo YH, Chen YM. Luo YH, et al. Transl Lung Cancer Res. 2013 Dec;2(6):442-4. doi: 10.3978/j.issn.2218-6751.2013.10.12. Transl Lung Cancer Res. 2013. PMID: 25806266 Free PMC article.

6

Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance.

Luo YH, Chen YM. Luo YH, et al. Transl Lung Cancer Res. 2014 Dec;3(6):368-9. doi: 10.3978/j.issn.2218-6751.2014.09.07. Transl Lung Cancer Res. 2014. PMID: 25806322 Free PMC article. No abstract available.

7

A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.

Luo YH, Tseng PC, Lee YC, Perng RP, Whang-Peng J, Chen YM. Luo YH, et al. Cancer Biomark. 2016;16(1):19-29. doi: 10.3233/CBM-150537. Cancer Biomark. 2016. PMID: 26484608

8

Induced Pluripotent Stem Cell-conditioned Medium Suppressed Melanoma Tumorigenicity Through the Enhancement of Natural-Killer Cellular Immunity.

Hsieh CT, Luo YH, Chien CS, Wu CH, Tseng PC, Chiou SH, Lee YC, Whang-Peng J, Chen YM. Hsieh CT, et al. Among authors: luo yh. J Immunother. 2016 May;39(4):153-9. doi: 10.1097/CJI.0000000000000117. J Immunother. 2016. PMID: 27023059

9

Spectrum of cancer risk among Taiwanese with chronic obstructive pulmonary disease.

Chiang CL, Hu YW, Wu CH, Chen YT, Liu CJ, Luo YH, Chen YM, Chen TJ, Su KC, Chou KT. Chiang CL, et al. Among authors: luo yh. Int J Clin Oncol. 2016 Oct;21(5):1014-1020. doi: 10.1007/s10147-016-0983-z. Epub 2016 May 6. Int J Clin Oncol. 2016. PMID: 27154177

10

Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung.

Luo YH, Wu CH, Huang CY, Wu CW, Wu WS, Lee YC, Whang-Peng J, Chen YM. Luo YH, et al. Asia Pac J Clin Oncol. 2017 Oct;13(5):e440-e448. doi: 10.1111/ajco.12576. Epub 2016 Aug 23. Asia Pac J Clin Oncol. 2017. PMID: 27550395

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

571 results

Search Page